Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy

被引：18

作者：

Nghiem, Paul

Bhatia, Shailender

Brohl, Andrew Scott

Hamid, Omid

Mehnert, Janice M.

Terheyden, Patrick

Shih, Kent C.

Brownell, Isaac

Lebbe, Celeste

Lewis, Karl D.

Linette, Gerald P.

Milella, Michele

Hennessy, Meliessa

Bajars, Marcis

Hicking, Christine

D'Angelo, Sandra P.

机构：

[1] Univ Washington, Med Ctr, South Lake Union, Seattle, WA 98195 USA

[2] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] Angeles Clin & Res Inst, Los Angeles, CA USA

[5] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[6] Univ Lubeck, Dept Dermatol, Lubeck, Germany

[7] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[8] NCI, Bethesda, MD 20892 USA

[9] Univ Paris Diderot, CIC Dept, AP HP, Paris, France

[10] Univ Paris Diderot, Dept Dermatol, AP HP, Paris, France

[11] Univ Colorado Denver, Sch Med, Aurora, CO USA

[12] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

[13] IRCCS, Ist Nazl Tumori Regina Elena, Rome, Italy

[14] EMD Serono Inc, Billerica, MA USA

[15] Merck KGaA, Darmstadt, Germany

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[17] Weill Cornell Med Coll, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9507

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9507

引用

页数：2

共 42 条

[1] Two-Year Efficacy and Safety Update from JAVELIN Merkel 200 Part A: A Registrational Study of Avelumab in Metastatic Merkel Cell Carcinoma Progressed on Chemotherapy
Sandhu, S.
Nghiem, P.
Bhatia, S.
Brohl, A. S.
Hamid, O.
Mehnert, J. M.
Terheyden, P.
Shih, K. C.
Brownell, I.
Lebbe, C.
Lewis, K. D.
Linette, G. P.
Milella, M.
Hennessy, M.
Bajars, M.
Hicking, C.
D'Angelo, S. P.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 52 - 53
[2] Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy
van Hagen, Tom
Sandhu, Shahneen
Nghiem, Paul
Bhatia, Shailender
Brohl, Andrew S.
Hamid, Omid
Mehnert, Janice M.
Terheyden, Patrick
Shih, Kent C.
Brownell, Isaac
Lebbe, Celeste
Lewis, Karl D.
Linette, Gerald P.
Milella, Michele
Hennessy, Meliessa
Bajars, Marcis
Hicking, Christine
D'Angelo, Sandra P.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 172 - 173
[3] 18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.
D'Angelo, Sandra P.
Russell, Jeffery Scott
Bhatia, Shailender
Hamid, Omid
Mehnert, Janice M.
Terheyden, Patrick
Shih, Kent C.
Brownell, Isaac
Lebbe, Celeste
Lewis, Karl D.
Linette, Gerald P.
Milella, Michele
Hennessy, Meliessa
Bajars, Marcis
Zwiener, Isabella
Nghiem, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[4] Patient Experiences with Avelumab in Treatment-Naive Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial
Lambert, Jeremy
Marrel, Alexia
D'Angelo, Sandra P.
Burgess, Melissa A.
Chmielowski, Bartosz
Fazio, Nicola
Gambichler, Thilo
Grob, Jean-Jacques
Lebbe, Celeste
Robert, Caroline
Russell, Jeffrey
Guezel, Guelseren
Bharmal, Murtuza
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2020, 13 (04): : 457 - 467
[5] Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial
Jérémy Lambert
Alexia Marrel
Sandra P. D’Angelo
Melissa A. Burgess
Bartosz Chmielowski
Nicola Fazio
Thilo Gambichler
Jean-Jacques Grob
Céleste Lebbé
Caroline Robert
Jeffrey Russell
Gülseren Güzel
Murtuza Bharmal
The Patient - Patient-Centered Outcomes Research, 2020, 13 : 457 - 467
[6] First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
D'Angelo, S. P.
Lebbe, C.
Mortier, L.
Brohl, A. S.
Fazio, N.
Grob, J. -J.
Prinzi, N.
Hanna, G. J.
Hassel, J. C.
Kiecker, F.
von Heydebreck, A.
Guezel, G.
Nghiem, P.
ESMO OPEN, 2024, 9 (05)
[7] Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
D'Angelo, Sandra P.
Lebbe, Celeste
Nghiem, Paul
Brohl, Andrew S.
Mrowiec, Thomas
Leslie, Trent
Georges, Sara
Guzel, Gulseren
Shah, Parantu
CLINICAL CANCER RESEARCH, 2024, 30 (19) : 4352 - 4362
[8] FIRST-LINE AVELUMAB TREATMENT IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA: 4-YEAR FOLLOW-UP FROM THE JAVELIN MERKEL 200 TRIAL
D'Angelo, Sandra
Lebbe, Celeste
Mortier, Laurent
Brohl, Andrew
Fazio, Nicola
Grob, Jean-jaques
Prinzi, Natalie
Hanna, Glenn
Hassel, Jessica
Kiecker, Felix
von Heydebreck, Anja
Guezel, Guelseren
Nghiem, Paul
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A633 - A633
[9] Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
Lebbe, C.
Nghiem, P.
Bhatia, S.
Mortier, L.
Brohl, A. S.
Jacob, N.
Tyroller, K.
Hoffman, J.
D'Angelo, S. P.
ANNALS OF ONCOLOGY, 2024, 35 : S744 - S745
[10] Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Kaufman, Howard L.
Russell, Jeffery S.
Hamid, Omid
Bhatia, Shailender
Terheyden, Patrick
D'Angelo, Sandra P.
Shih, Kent C.
Lebbe, Celeste
Milella, Michele
Brownell, Isaac
Lewis, Karl D.
Lorch, Jochen H.
von Heydebreck, Anja
Hennessy, Meliessa
Nghiem, Paul
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

← 1 2 3 4 5 →